REGENXBIO (NASDAQ:RGNX) Downgraded to Sell Rating by Wall Street Zen

REGENXBIO (NASDAQ:RGNX) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities research analysts also recently issued research reports about the stock. Stifel Nicolaus increased their target price on shares of REGENXBIO from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, December 19th. Barclays initiated coverage on REGENXBIO in a research note on Tuesday. They set an “overweight” rating and a $37.00 price objective for the company. Leerink Partners lifted their target price on REGENXBIO from $16.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of REGENXBIO in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada increased their price target on REGENXBIO from $17.00 to $19.00 and gave the stock an “outperform” rating in a report on Friday, November 7th. Seven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $30.00.

REGENXBIO Trading Down 3.8%

Shares of RGNX opened at $11.16 on Friday. The company’s 50 day simple moving average is $13.72 and its 200-day simple moving average is $11.31. The firm has a market cap of $564.92 million, a PE ratio of -3.22 and a beta of 1.07. REGENXBIO has a 12-month low of $5.03 and a 12-month high of $16.19.

REGENXBIO (NASDAQ:RGNX) last released its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) EPS for the quarter, beating the consensus estimate of ($1.38) by $0.18. REGENXBIO had a negative net margin of 110.29% and a negative return on equity of 78.29%. The firm had revenue of $29.73 million during the quarter, compared to the consensus estimate of $24.41 million. As a group, equities research analysts forecast that REGENXBIO will post -4.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. JPMorgan Chase & Co. raised its position in REGENXBIO by 4.8% in the third quarter. JPMorgan Chase & Co. now owns 4,037,248 shares of the biotechnology company’s stock worth $38,959,000 after acquiring an additional 185,223 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of REGENXBIO by 1.1% during the 4th quarter. Vanguard Group Inc. now owns 3,374,140 shares of the biotechnology company’s stock worth $48,588,000 after purchasing an additional 36,042 shares in the last quarter. Assenagon Asset Management S.A. grew its stake in shares of REGENXBIO by 64.5% during the 4th quarter. Assenagon Asset Management S.A. now owns 1,160,380 shares of the biotechnology company’s stock worth $16,709,000 after purchasing an additional 454,977 shares during the period. Geode Capital Management LLC increased its holdings in shares of REGENXBIO by 1.9% in the 2nd quarter. Geode Capital Management LLC now owns 1,128,521 shares of the biotechnology company’s stock valued at $9,267,000 after purchasing an additional 21,575 shares in the last quarter. Finally, Integral Health Asset Management LLC lifted its stake in shares of REGENXBIO by 57.1% in the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company’s stock valued at $10,615,000 after purchasing an additional 400,000 shares during the period. Institutional investors and hedge funds own 88.08% of the company’s stock.

REGENXBIO News Summary

Here are the key news stories impacting REGENXBIO this week:

• Positive Sentiment: Chardan Capital reaffirmed a “buy” on RGNX and set a $52 price target, signaling strong upside from current levels. Chardan Reaffirmation
• Neutral Sentiment: Zacks notes RGNX recently jumped on higher volume (a 5.4% move) but warns that recent downward earnings‑estimate revisions could limit near‑term upside; investors should watch subsequent analyst revisions. Zacks: Soars 5.4%
• Positive Sentiment: Leerink (reported by Yahoo Finance) called the earlier selloff “an overreaction” to the clinical hold, suggesting a recovery is possible if forthcoming safety data and disclosures calm investors. Leerink Commentary
• Negative Sentiment: The U.S. FDA placed clinical holds on RGX‑111 and RGX‑121 following identification of a tumor in a trial participant (disclosed in a Form 8‑K on Jan. 28), a direct driver of the recent sharp stock decline and operational uncertainty for those programs. FDA Clinical Hold / Form 8‑K
• Negative Sentiment: Multiple law firms (Levi & Korsinsky, Pomerantz) have launched investigations alleging potential disclosure gaps or securities claims tied to the FDA action, increasing legal and reputational risk. Levi & Korsinsky Investigation Pomerantz Investigation
• Negative Sentiment: Media coverage (Investing.com, AAII, MSN) documents a steep market reaction and broad selloff following the FDA notice; near‑term stock performance will hinge on company updates, the FDA’s path to lifting holds, and any further safety disclosures. Investing.com Coverage

About REGENXBIO

REGENXBIO Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies using its proprietary NAV® AAV (adeno‐associated virus) platform. The company engineers next‐generation AAV vectors designed to deliver functional genes to targeted cells, aiming to address a range of rare genetic diseases and ocular, metabolic and neurologic disorders. REGENXBIO’s pipeline features several product candidates in various stages of preclinical and clinical development, including RGX-314 for wet age‐related macular degeneration, RGX-121 for mucopolysaccharidosis II (Hunter syndrome) and RGX-121 for other rare lysosomal storage diseases.

In addition to its internally funded programs, REGENXBIO has established partnerships with major biopharmaceutical companies to advance its NAV technology.